NasdaqGS:AMGNBiotechs
EU Approval Of IMDYLLTRA Puts Amgen’s Lung Cancer Ambitions In Focus
European Commission approves Amgen's IMDYLLTRA (tarlatamab) for adults with extensive-stage small cell lung cancer as a second-line treatment.
Decision follows positive Phase 3 results showing a survival benefit over standard chemotherapy.
Approval adds a new marketed therapy to Amgen's oncology portfolio in a high unmet medical need area.
For investors following Amgen (NasdaqGS:AMGN), the European Commission's green light for IMDYLLTRA arrives with the stock trading around $328.26. Shares...